Skip to main content
. 2020 Jun 19;12(6):665. doi: 10.3390/v12060665

Figure 2.

Figure 2

Figure 2

Inhibitor titration of uninfected and latent HIV-1-infected cells. In this process, 5 × 104 cells were plated with different concentrations of kinase inhibitors and allowed to incubate for 48 h prior to a Cell-Titer Glo assay. (A) CEM, ACH2, U937, and U1 cells treated with dasatinib (c-Src inhibitor) at 0, 0.1, 1, or 5 µM. (B) CEM, ACH2, U937, and U1 cells treated with LY294002 (PI3K inhibitor) at 0, 1, 10, or 25 µM. (C) CEM, ACH2, U937, and U1 cells treated with MK2206 (AKT-1 inhibitor) at 0, 0.01, 0.1, or 1 µM. (D) CEM, ACH2, U937, and U1 cells treated with WP1066 (STAT3 inhibitor) at 0, 1, 5, or 10 µM. (E) CEM, ACH2, U937, and U1 cells treated with bufalin (SRC-1 inhibitor) at 0, 1, 5, or 25 nM. (F) ACH2 and U1 cells treated with gefitinib (EGFR inhibitor) at 0, 1, 5, or 10 µM. (G) ACH2 and U1 cells treated with rapamycin (mTOR inhibitor) at 0, 10, 50, or 150 nM. Student’s t-tests compared untreated cells with cells treated with drugs. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Error bars, S.D.